Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer

BACKGROUND: Aberrant PI3K signalling is implicated in trastuzumab resistance in HER2-positive gastric cancer (GC). The role of PI3K or MEK inhibitors in sensitising HER2-positive GCs to trastuzumab or in overcoming trastuzumab resistance is unclear. METHODS: Using mass spectrometry-based genotyping...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Transl Med
Main Authors: Mezynski, M. Janusz, Farrelly, Angela M., Cremona, Mattia, Carr, Aoife, Morgan, Clare, Workman, Julie, Armstrong, Paul, McAuley, Jennifer, Madden, Stephen, Fay, Joanna, Sheehan, Katherine M., Kay, Elaine W., Holohan, Ciara, Elamin, Yasir, Rafee, Shereen, Morris, Patrick G., Breathnach, Oscar, Grogan, Liam, Hennessy, Bryan T., Toomey, Sinead
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2021
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8088633/
https://ncbi.nlm.nih.gov/pubmed/33933113
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-021-02842-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados